OncoMatch/Clinical Trials/NCT06958328
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Is NCT06958328 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for locally advanced unresectable pancreatic ductal adenocarcinoma.
Treatment: Capecitabine · Fluorouracil · Gemcitabine · Irinotecan Hydrochloride · Irinotecan Sucrosofate · Leucovorin Calcium · Nab-paclitaxel · Oxaliplatin — This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care options include additional chemotherapy, observation, or standard lower-dose radiation therapy. These treatments may delay tumor growth but have not been shown to improve survival. Radiation therapy uses high energy X-rays to kill cancer cells and shrink tumors. Dose-escalated radiation therapy involves the precise delivery of higher doses to the tumor, often over a shorter period of time. This trial assesses whether using dose-escalated radiation therapy can prolong survival.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage III, STAGE II, STAGE III, STAGE IV (other)
Locally advanced unresectable disease (as defined per the National Comprehensive Cancer Network [NCCN] guidelines and institutional tumor board review)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic chemotherapy (FOLFIRINOX, NALIRIFOX, gemcitabine/nab-paclitaxel) — pre-study entry for locally advanced pancreatic cancer
the patient must have received 4-8 months of active chemotherapy with FOLFIRINOX or NALIRIFOX or gemcitabine/nab-paclitaxel
Cannot have received: radiation therapy to region of study cancer with field overlap
Exception: prior non-overlapping radiation (e.g., breast, head and neck, extremity) is permitted
Has the patient had prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Lab requirements
Liver function
ALT and AST ≤ 3 x ULN; if baseline CA19-9 > 37 U/mL, concurrent bilirubin must be ≤ 1.5 x ULN
Cardiac function
No cardiac condition that was the primary reason for hospitalization in the last 6 months; NYHA Functional Classification II or better
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN); If baseline CA19-9 > 37 U/mL the concurrent bilirubin must be ≤ 1.5 x ULN; No cardiac condition that was the primary reason for hospitalization in the last 6 months; NYHA Functional Classification II or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Arizona Center for Cancer Care - Gilbert · Gilbert, Arizona
- Arizona Center for Cancer Care-Peoria · Peoria, Arizona
- Banner-University Medical Center Phoenix · Phoenix, Arizona
- Arizona Center for Cancer Care - Phoenix · Phoenix, Arizona
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06958328 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy to region of study cancer with field overlap disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or STAGE II or STAGE III or STAGE IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages